A
Affectis Pharmaceuticals
Biotech & Life Sciences · Dortmund, Germany · Founded 2002
Developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases MoreLess
Affectis is a biopharmaceutical company focused on the development of novel drugs aimed at treating psychiatric and inflammatory disorders. The company operates in the pharmaceutical and healthcare market, targeting conditions that have significant unmet medical needs. Affectis serves a diverse range of clients, including healthcare providers, hospitals, and research institutions. The business model revolves around the research, development, and commercialization of pharmaceutical products. Revenue is generated through the sale of these drugs, as well as potential licensing agreements and partnerships with other pharmaceutical companies. The company leverages its expertise in biopharmaceuticals to bring innovative treatments to market, addressing critical health issues and improving patient outcomes.
Keywords: biopharmaceutical, novel drugs, psychiatric disorders, inflammatory disorders, healthcare, pharmaceutical market, research, development, commercialization, patient outcomes.
Talent graph
Affectis Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Affectis Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.



Global footprint
Where Affectis Pharmaceuticals has talent and traffic
Market sentiment
What the market is saying about Affectis Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Affectis Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Affectis Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.